Spenser Lin No Comments

News Healthcare Deals, Investments & Update Week ending Jan 12th 2026

LECO_Weekly-Healthcare-News_1-12-2026Download
  1. 44th Annual J.P. Morgan Healthcare Conference 2026 Commences in San Francisco with Industry Leaders and Dealmakers The world’s largest healthcare investment symposium kicks off today, running through January 15, 2026, at the Westin St. Francis in San Francisco, bringing together global industry leaders, emerging companies, innovative technology creators, and the investment community. The conference features keynote addresses from JPMorgan Chase CEO Jamie Dimon, CMS Administrator Dr. Mehmet Oz, and FDA Commissioner Dr. Marty Makary. Key panel discussions include OpenAI in healthcare, federated AI in oncology, women’s health innovation, and ARPA-H initiatives. Major pharmaceutical companies including Eli Lilly, Novo Nordisk, Teva, AstraZeneca, Pfizer, Merck, Moderna, and Samsung Biologics are presenting throughout the four-day event. (Link)
  2. Anthropic Launches Claude for Healthcare at JPM26, Partners with Banner Health, Stanford Health Care, and Novo Nordisk The AI company debuted Claude for Healthcare, a HIPAA-ready platform designed for payers, providers, and health systems, extending its Claude model into regulated healthcare environments. It offers secure integrations with databases such as CMS Coverage, ICD‑10, PubMed, and the National Provider Identifier Registry, supporting workflows like medical coding, claims management, and prior authorization. The launch, following Claude for Life Sciences, adds specialized tools for interoperability, clinical documentation, and real‑time analytics. Existing users—including Banner Health, Stanford Health Care, Sanofi, AbbVie, and Genmab—use Claude to automate administrative workflows and improve clinical and operational efficiency. (Link)
  3. Eli Lilly (NYSE: LLY) to acquire Ventyx Biosciences (NASD: VTYX) for $1.2 Billion to Advance Oral Inflammatory Disease Therapies The Indianapolis-based pharmaceutical giant will pay $14.00 per share in an all-cash transaction representing a 62% premium to Ventyx’s 30-day volume-weighted average trading price. The San Diego clinical-stage company develops NLRP3 inhibitors targeting chronic inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. Dr. Daniel Skovronsky emphasized the acquisition strengthens Lilly’s capabilities in delivering advances for patients with challenging diseases. Entities affiliated with New Science Ventures and all Ventyx directors and officers signed voting agreements representing approximately 10% of outstanding common stock. The transaction requires Ventyx stockholder approval and regulatory clearances, expected to close in first half 2026. (Link)
  4. Aktis Oncology (NASD: AKTS) raises $318M in Upsized IPO with backing from Bristol Myers Squibb, Merck’s MRL Ventures Fund, Eli Lilly and Pfizer to Advance Radiopharmaceutical Cancer Therapies The company sold 17.6 million shares at $18 each, exceeding its initial estimate of 11.8 million shares priced between $16-$18, making it the largest biotech IPO since last year’s offerings from Metsera, LB Pharmaceuticals, and MapLight Therapeutics. Proceeds could increase by $47.6 million if underwriters exercise their option to purchase 2.6 million additional shares. The biotech allocated $140-$150 million to fund its ongoing U.S. phase 1b study of miniprotein radiopharmaceutical Ac-AKY-1189 for Nectin-4 expressing tumours, with results expected first quarter 2027, and $70-$80 million for phase 1b launch of Ac-AKY-2519 targeting B7-H3 expressing tumours. Shares begin trading Friday on Nasdaq under ticker “AKTS.” (Link)
  5. Eli Lilly (NYSE: LLY) partners with InduPro in Deal Worth Up to $950M to Develop Cancer Therapeutics The Indianapolis-based pharmaceutical company will collaborate on up to three undisclosed cancer targets while making an equity investment of undisclosed amount. InduPro will lead early discovery using its AI/ML-enabled membrane interactomics platform to create bi- and tri-specific therapeutics. The Seattle and Cambridge-based biotech analyses tumour antigen proximity to discover disease-specific protein-target pairs for developing bispecific antibody-drug conjugates and multispecific T-cell engagers. This marks InduPro’s second major pharma partnership following December’s collaboration with Sanofi on bispecific PD-1 agonist antibodies. InduPro raised $85 million in series A financing in June 2024, with lead candidate IDP-003 currently in studies enabling human testing. (Link)
  6. Haemonetics (NYSE: HAE) acquires Vivasure Medical Limited for €100M Upfront Plus Contingent Payments The Boston-based medical technology company purchased the Galway, Ireland firm to expand its presence in large-bore closure markets for structural heart and endovascular procedures. Vivasure’s PerQseal® Elite system uses a proprietary bioabsorbable patch to seal arteriotomies and venotomies up to 26 F from inside the vessel. The ELITE arterial study showed 0% major complications at thirty-day follow-up with immediate median time to haemostasis. Additional contingent consideration of up to €85 million depends on sales growth and milestone achievement. CEO Andrew Glass emphasized joining Haemonetics provides global scale to accelerate technology availability worldwide. (Link)
  7. Merck (NYSE: MRK) Completes $9 Billion Acquisition of Cidara Therapeutics for CD388 Influenza Drug Merck finalized its acquisition of Cidara through a tender offer at $221.50 per share, with 85.96% of outstanding shares tendered. The deal brings CD388, a potentially first-in-class long-acting antiviral for influenza prevention, into Merck’s respiratory portfolio. The investigational drug-Fc conjugate shows broad activity against influenza A and B strains and is designed to provide season-long protection for high-risk individuals without requiring immune response activation. Cidara becomes a wholly owned subsidiary, with its stock delisted from Nasdaq. (Link)
  8. IntelyCare acquires CareRev to Expand Healthcare Workforce Management Platform The tech-enabled staffing platform purchased the acute care labour marketplace to create a comprehensive clinical labour solution addressing critical workforce shortages across healthcare settings. The combined entity will operate both brands, offering integrated services spanning job boards, recruiting, contingent labour, and internal resource pools through a single technology platform. CEO Matthew Levesque emphasized the merger helps facilities efficiently manage permanent staff and contingent workers while maintaining care quality. IntelyCare previously achieved unicorn status with a $115 million Series C round in April 2022. Investors LRVHealth and Transformation Capital praised the strategic combination’s potential to lead workforce transformation in the healthcare sector. (Link)
  9. Verana Health merges with COTA to Expand Real-World Data Offerings Across Oncology and Specialties The combined entity will serve 17 of the top 20 global biopharma companies with access to over 95 million patients and 20,000 clinicians, including network expansion to more than 30 Academic Medical Centers. COTA’s oncology focus complements Verana Health’s existing data platforms in ophthalmology, urology, and neurology. The portfolio supports clinical trials, drug submissions, health economics research, and market-access strategies. Existing institutional investors committed an additional $52 million in equity investment. CEO Sujay Jadhav emphasized the combination raises standards for clinical expertise, data quality, and transparency across multiple therapeutic areas. (Link)
  10. Veritas Capital to acquire Majority Stake in Global Healthcare Exchange from Temasek and Warburg Pincus Veritas Capital will partner with existing shareholders to accelerate GHX’s growth strategy in healthcare supply chain software. The cloud-based platform connects providers and suppliers, serving Gartner’s top 25 U.S. healthcare systems and top 30 global medical-surgical suppliers. Through AI-driven automation and intelligent decision support, the company has delivered over $27 billion in savings over three years. The investment will enable faster product innovation, organic and inorganic growth opportunities, and enhanced AI capabilities to improve supply chain efficiency and patient care delivery. The transaction is expected to close in Q1 2026, subject to regulatory approvals. (Link)
  11. RadNet (NASD: RDNT) acquires Radiology Regional from LucidHealth, Expanding to Southwest Florida The acquisition brings 13 imaging centers across Naples, Cape Coral, Fort Myers, Port Charlotte and Sarasota into RadNet’s network. Radiology Regional has provided multi-modality imaging services including MRI, CT, PET/CT, mammography, ultrasound and X-ray for half a century. The expansion adds approximately 400 employees and 44 contracted radiologists to RadNet’s existing five Florida locations. RadNet plans to deploy its DeepHealth AI-powered innovations to enhance clinical accuracy and streamline imaging processes. The deal is projected to contribute approximately $100 million in revenue during 2026, supporting growing demand for advanced imaging services in Florida’s rapidly expanding population. (Link)
  12. Corewell Health and Quest Diagnostics Form Joint Venture for Laboratory Services in Michigan The 51%-49% joint venture, Diagnostic Lab of Michigan, LLC, will establish a 100,000-square-foot state-of-the-art facility at Corewell Health Southfield Center featuring automated microbiology and high-throughput molecular testing. Quest will provide Collaborative Lab Solutions including reference testing, professional management, workforce and supply chain services for all 21 Corewell Health hospital labs statewide, which will remain operational. The transaction is expected to close in Q1 2026, with most laboratory services beginning in 2026 and the new facility operational by Q1 2027. Existing patient service centers will continue operating under joint venture management until the new laboratory opens. (Link)

Venture and Other News  

  1. AirNexis secures $200M Series A Led by Frazier Life Sciences with OrbiMed, Goldman Sachs Alternatives, SR One; Licenses Haisco Pharmaceutical’s COPD Asset in $955M Deal Founded by Frazier Life Sciences, the California biotech obtained exclusive rights outside China to HSK39004 (AN01), a PDE3/4 inhibitor for chronic obstructive pulmonary disease, for $40 million upfront. Haisco will hold 19.9% equity and earn potential regulatory and commercial milestone payments plus royalties. The dual-mechanism inhaler launched three phase 2 trials in 2025, testing different dosage forms including inhalation suspension and powder designed to expand airways and reduce inflammation. The series A round included participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital and Enavate Sciences. CEO Maria Fardis, former Lassen Therapeutics chief, leads the startup. (Link)
  2. Pomelo Care banks $92M Series C Led by Stripes with Andreessen Horowitz, PLUS Capital, Atomico, BoxGroup, and SV Angel to Expand Virtual Women’s and Paediatric Healthcare The startup, now valued at $1.7 billion, is expanding beyond maternity care to reproductive health, paediatrics, hormonal health, and menopause services. Pomelo partners with health plans and employers, covering over 25 million lives and supporting nearly 7% of U.S. births. Independent studies show the platform reduces total care costs, lowers NICU and ER utilization, and delivers 3-5x ROI through outcomes including 37% fewer preterm births and 46% reduction in emergency room visits. The company has raised  ~ $171 million to date and recently launched a midlife care program demonstrating 88% symptom reduction in 60 days. (Link)
  3. Ventaris Surgical raises $30M Series A Led by Longitude Capital and Vensana Capital with Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners The San Carlos-based medical device company is developing a ureteroscopic system designed to improve complete stone clearance during kidney stone procedures. CEO Surag Mantri emphasized the technology removes unnecessary friction from surgeries, allowing surgeons to focus on achieving consistent outcomes. Varun Gupta of Longitude Capital and Justin Klein of Vensana Capital will join the Board of Directors alongside independent member Amir Abolfathi. Proceeds will support continued clinical development and advancement toward regulatory and commercial milestones. Maxwell Bikoff noted the technology addresses critical unmet needs in current standard of care for one of the most common urologic interventions. (Link)
  4. Canopy raises $22M Series B Led by 111° West Capital and ACME Capital to Expand Healthcare Staff Safety Platform The San Francisco-based company’s platform is deployed across 60 major U.S. health systems supporting over 300,000 healthcare workers in more than 1,200 buildings. The technology addresses workplace violence, which has increased 63% over the past five years, through discreet duress alerts and real-time situational awareness. Current clients include Boston Children’s Hospital, Thomas Jefferson University, and University of Michigan Health–Sparrow. CEO Shan Sinha emphasized the platform’s safety-first architecture as a core operational requirement. Bharat Sundaram, CEO of Hallmark Healthcare Solutions, joins the board. Funding will accelerate nationwide expansion and rollout of operational tools including Canopy Find and Canopy Track. (Link)
  5. Healthcare Investment and News Outlook for 2026 
    • LECO – 2026 Healthcare Investment Perspective (Link)
    • Pitchbook  – 2026 Healthcare Outlook (Link) 
    • Forbes – The Healthcare Industry Outlook For 2026 (Link) 
    • Deloitte – 2026 US Health Care Outlook (Link) 
    • E&Y  – Healthcare Sector Outlook: growing amid headwinds in 2026  (Link) 
    • PwC  – US Deals 2026 outlook Health services (Link) 
Neil Johnson No Comments

2026 Healthcare Industry Outlook

2026 Healthcare Investment Perspective

Healthcare enters 2026 in an early-cycle recovery, with stabilizing capital markets, disciplined dealmaking, and innovation-driven growth replacing the caution of 2025. Moderating interest rates and greater policy clarity are unlocking pent-up M&A and venture activity, while artificial intelligence emerges as the pivotal force transforming productivity, valuations, and competitive positioning across the sector.

Key Themes

  • AI as Structural Driver: AI is delivering measurable gains—potentially lifting biopharma clinical trial success rates significantly above historical levels, automating administrative workflows, and enabling scalable care. AI-native assets command 2x valuation premiums, reflecting superior capital efficiency and ROI potential, especially in early-stage biopharma where returns could exceed prior strong vintages.
  • Decentralized Delivery: Care continues shifting to lower-cost outpatient, ambulatory, behavioral health, and post-acute settings (40-60% cost savings vs. hospitals). These subsectors offer recurring revenue, consolidation opportunities, and alignment with payer affordability pressures amid ~8.5% medical cost inflation.
  • Capital Markets Reacceleration: Venture funding rebounds in healthtech, medtech (multi-year highs in AI diagnostics/surgical), and early-stage biopharma. M&A focuses on bolt-ons, carve-outs, and capability builds; private equity favors cash-generative platforms with moderate regulatory risk. The IPO window is selectively reopening for tech-enabled issuers, enhancing exit visibility.

Subsector Highlights

  • Biopharma: Intense competition in metabolic therapies drives upstream acquisitions; AI de-risking attracts capital to early assets.
  • Medtech: Strategic buyers target AI innovations; frontier technologies advance toward commercialization.
  • Healthtech/Services: Convergence accelerates as PE-backed HCIT acquires VC-backed digital platforms; behavioral health and ASCs remain prime roll-up targets.

Risks: Regulatory uncertainty (reimbursement, AI governance, trade policy), cybersecurity, workforce shortages, and valuation discipline in returning capital flows.

Conclusion 2026 favors selective, execution-focused investments in AI-integrated, scalable platforms within high-demand, efficient delivery models. This measured recovery prioritizes operational value creation over leverage, positioning disciplined investors for durable returns in a resilient sector.

Contact us today to discuss your strategic options or capital needs info@lawrenceevans.com

Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Jan 5th 2026

LECO_Weekly-Healthcare-News_1-5-2026Download
  • Happy New Year –  Healthcare Investment and News Outlook for 2026
    • Pitchbook  – 2026 Healthcare Outlook (Link)
    • Forbes – The Healthcare Industry Outlook For 2026 (Link)
    • Healthcare Sector Outlook: growing amid headwinds in 2026  (Link)
    • PwC  – US Deals 2026 outlook Health services (Link)
    • Deloitte – 2026 US Health Care Outlook (Link)
  • FONAR Corporation (NASD: FONR) CEO Timothy Damadian Leads $19 Per Share Take-Private Acquisition with OceanFirst Bank Financing The buyer group, including management members, board directors, and third-party investors, will acquire all outstanding shares not already owned by the group at prices representing a 31.5% premium to pre-announcement closing and 39.7% premium to the 90-day average. A special committee of disinterested directors unanimously recommended the deal after independent review. Financing includes $35 million from committed debt, $10 million in subordinated debt, and $45 million in equity contributions, with no financing contingencies. The transaction requires majority approval from all voting shares and disinterested shareholders, expected to close in fiscal Q3 2026, after which shares will be delisted from Nasdaq. (Link)
  • Insilico Medicine partners with Servier in $888M AI-Driven Cancer R&D Deal Following Hong Kong IPO The collaboration will leverage Insilico’s Pharma.AI platform to discover and develop drugs targeting challenging cancer targets, with Insilico receiving $32 million in upfront and R&D payments. Insilico leads AI-driven discovery while Servier shares R&D costs and handles clinical validation and commercialization. The agreement follows Insilico’s recent Hong Kong listing that raised $293 million and builds on its 2025 momentum, including a $110 million venture round and partnerships with pharmaceutical companies like Eli Lilly. For Servier, this represents another strategic move in its ambition to become a leading innovative pharma by 2030, following recent deals worth $450 million with Kaerus Bioscience and $210 million with Ideaya Biosciences. (Link)
  • PathoCare Holdings Receives $1.75B Valuation in Third-Party Tender Offer, Expands Financing Round with Lehrer Financial Assessment The secondary share purchase follows the company’s previous $150 million venture investment, recapitalization, acquisition, and $500 million secondary tender offer independently valued by Houston-based Lehrer Financial. PathoCare has appointed an independent financial advisory firm to conduct a formal fairness opinion and valuation review using recognized techniques, peer comparisons, and market data. The company simultaneously expanded its private equity financing round from $25 million to $50 million due to heightened institutional interest. Proceeds will fund product development, intellectual property expansion, regulatory readiness, engineering, and commercialization of its flagship PathoWand point-of-care diagnostic platform. (Link)
  • Maimonides Health Joins NYC Health + Hospitals Under Mayor Eric Adams Deal to Stabilize Brooklyn Healthcare The financially struggling Maimonides Health, a century-old community fixture in Brooklyn, will become part of the city’s public health system pending regulatory approval expected before April 1. The partnership will enable Maimonides—which operates three hospitals and 80+ sites serving 600,000 outpatients and 35,000 inpatients annually—to receive higher Medicaid reimbursement rates and access NYC Health + Hospitals’ electronic health records platform. Over 80% of Maimonides’ admitted patients rely on Medicare or Medicaid, which reimburse only 60 cents per dollar compared to commercial insurance, contributing to annual losses of tens of millions, including $165 million in 2021. (Link)
  • Marlborough Hospital Becomes UMass Memorial Medical Center Campus Following Massachusetts Public Health Council Approval The 79-bed facility, previously affiliated with UMass Memorial Health under an independent medical license, officially merged on January 1 after approval in July. The integration brings enhanced services including an expanded emergency department, new CT scanner, outpatient clinic, and improved cancer treatment capabilities. Despite the organizational change, patients will continue seeing the same medical staff while gaining broader access to specialty care, advanced technologies, and tertiary services through the coordinated clinical team, keeping more healthcare services available locally within the system’s smallest campus. (Link)
  • Proactive MD acquires California Ophthalmology Practices, Expands Value-Based Care Network The Los Angeles-based healthcare leader adds multiple ophthalmology practices following recent expansions in Indiana, Texas, and Colorado. This acquisition strengthens Proactive MD’s integrated healthcare solutions aimed at improving patient outcomes and reducing costs for employer-sponsored healthcare, health plan providers, and third-party administrators. Since launching its growth strategy in 2021, the company has expanded offerings to include clinical diagnostics, pathology services, occupational health, virtual and urgent care, healthcare technology, pharmacy products, and a 340B pharmacy provider network. The organization operates as the only national primary care provider owning and operating its own labs, pathology groups, pharmacies, 340B networks, and healthcare technology platforms. (Link)
  • Biobeat Technologies closes $50 million Series B led by Ally Bridge Group, OrbiMed Advisors and Elevage Medical to expand U.S. commercialization of FDA‑cleared cuff‑less ambulatory blood pressure monitoring system The capital will fund a field sales team and commercial expansion for Biobeat’s disposable patch device, which monitors blood pressure continuously for 24 hours without disruptive inflation cycles, allowing patients to maintain daily activities and sleep undisturbed. At test completion, the device is discarded and a high-quality report appears automatically in electronic medical records within seconds. The company welcomed Steven Plachtyna of Ally Bridge, Dina Chaya of OrbiMed and Evan Melrose of Elevage to its Board of Directors, underscoring its ambition to establish ABPM as a standard of care for diagnosing and titrating anti-hypertensive medications for the more than 100 million hypertensive patients in the United States. (Link)
  • Nacuity Pharmaceuticals raises $12.89 Million Led by Foundation Fighting Blindness’ Retinal Degeneration Fund and National Neurovision Research Institute The Fort Worth-based clinical-stage biotech developing antioxidant therapies for blinding eye diseases caused by oxidative stress secured $12.89 million in funding led by Foundation Fighting Blindness’ Retinal Degeneration Fund and National Neurovision Research Institute, with participation from undisclosed investors. This round brings the company’s total funding to $40.59 million. The capital supports Nacuity’s advancement of its antioxidant therapeutic pipeline targeting retinal degenerative conditions. The involvement of specialized ophthalmology-focused investors underscores confidence in the company’s approach to treating oxidative stress-related vision loss and its potential to address unmet needs in blinding eye disease treatment. (Link)
  • Alume Biosciences raises $5.32 Million in Series C Venture Funding Alume Biosciences secured $5.32 million in Series C venture funding as of December 31, 2025. This capital injection supports the company’s ongoing development and expansion efforts. The funding round demonstrates continued investor confidence in the bioscience company’s business model and technological platform. The specific use of proceeds and details regarding lead investors were not disclosed in the announcement. This represents a significant milestone in the company’s growth trajectory as it advances its research, development, and commercialization initiatives within the biosciences sector. (Link)
Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Dec 22nd 2025

LECO_Weekly-Healthcare-News_12-15-2025-1Download
  • Medline (NASD: MDLN) soars 41% in Nasdaq debut after IPO backed by Blackstone, Carlyle, and Hellman & Friedman, raising $6.26 billion in 2025’s largest offering Medline’s IPO drew strong investor interest, valuing the firm at $46 billion after a 41% stock surge. Generating $977 million in profit on $20.6 billion in revenue, the company’s global manufacturing network limits tariff risks. Its steady, cash-rich model contrasts with typical volatile, high-growth market entrants. (Link)
  • Cencora (NYSE: COR) (formerly AmerisourceBergen) to acquire majority stake in OneOncology in $5 billion deal, after already holding a minority position, bolstering community oncology network and specialty distribution strategy The deal combines debt financing and an equity rollover to maintain physician autonomy while integrating OneOncology’s nationwide network within Cencora’s platform. The partnership enhances clinical trials, care coordination, and technology access, supporting community-based cancer care. Analysts see the transaction as a strong vote of confidence in oncology’s growth potential. (Link)
  • BioMarin (NASD: BMRN) to acquire Amicus Therapeutics (NASD: FOLD) for $4.8 billion, expanding rare disease portfolio with Galafold and Pombiliti-Opfolda The acquisition strengthens BioMarin’s rare disease pipeline by adding Amicus’ Galafold and Pombiliti-Opfolda therapies and kidney candidate DMX-200. These assets complement BioMarin’s enzyme replacement treatments and Voxzogo, supporting revenue growth and global expansion. Analysts view the deal as a strategic fit, reflected in BioMarin’s post-announcement stock surge. (Link)
  • Matt Holt to lead creation of Thoreau, a $30 billion AI‑enabled health‑tech venture combining New Mountain Capital’s Datavant, Swoop, Machinify, Smarter Technologies and Office Ally The deal would combine five healthcare tech companies into one AI-focused platform aimed at cutting medical costs for payers and providers. New Mountain Capital is weighing a structure that returns about 12 billion dollars in cash plus equity and warrants to its investors, exceeding prior portfolio valuations. (Link)
  • HCAP Partners invests in Puzzle Healthcare to scale post‑acute care coordination platform across U.S. skilled nursing facilities The investment will accelerate Puzzle Healthcare’s expansion of post-acute care coordination services that track patients for 90 days after skilled nursing stays. Operating in 230 facilities across 15 states, Puzzle uses data-driven workflows to reduce readmissions, lower costs, and safeguard providers from Medicare penalties through improved care continuity. (Link)
  • Medtronic plc (NYSE: MDT) and MiniMed move toward Nasdaq listing with S‑1 filing for diabetes business IPO The S‑1 filing initiates Medtronic’s plan to spin off its Diabetes unit as MiniMed, which intends to trade on Nasdaq under “MMED.” The IPO and potential split‑off structure depend on regulatory approval and market conditions. MiniMed will focus on AI‑enabled insulin delivery and continuous glucose monitoring technologies. (Link)
  • Philips to acquire SpectraWAVE to advance AI‑enabled intravascular coronary imaging and physiology through HyperVue and X1‑FFR The acquisition integrates SpectraWAVE’s X1‑FFR software, which measures coronary blood flow from angiograms, with its HyperVue imaging platform combining OCT and NIRS to visualize arterial plaque. Philips aims to unify AI-driven imaging and physiology tools to improve stent placement accuracy and standardize coronary disease treatment quality worldwide. (Link)
  • HealthStream (NASD: HSTM) acquires MissionCare Collective in deal valued up to $40 million to build largest U.S. caregiver career network The deal brings MissionCare Collective’s 5.2‑million caregiver network and platforms like myCNAjobs and CoachUp Care into HealthStream’s hStream ecosystem. It expands workforce solutions to home health and long‑term care providers, addressing caregiver shortages and aging‑population demands through enhanced recruiting, training, and retention tools supported by cash, stock, and earnout terms. (Link)
  • XOMA Royalty (NASDAQ: XOMA) to acquire Generation Bio (NASDAQ: GBIO) gaining exposure to Moderna collaboration and ctLNP nucleic acid delivery platform The transaction gives Generation Bio shareholders cash and contingent value rights linked to cash reserves, lease savings, and potential revenues from the Moderna partnership and ctLNP platform. Executed through a tender offer and merger, the deal has 15% shareholder support and is expected to close by February 2026. (Link)
  • Accordion acquires Pinnacle Healthcare Advisors, via its financial sponsors Charlesbank Capital Partners and Motive Partners, to build scaled revenue cycle management platform for health systems and healthcare investors The acquisition merges Pinnacle’s expertise in cash acceleration, AR reduction, and EHR optimization with Accordion’s AI-driven RCM Center of Excellence. The combined platform aims to help health systems tackle margin pressures, payer complexity, and denial rates by improving revenue performance through advanced analytics and integrated operational support. (Link)
  • INVO Fertility (NASD: IVF) to acquire Indiana clinic Family Beginnings to expand Midwest fertility footprint after $4.0M private placement The acquisition supports INVO Fertility’s U.S. expansion strategy centered on assisted reproductive technology, including INVOcell-based intravaginal culture. Family Beginnings adds a reputable Indiana clinic with $1.2 million in annual revenue and a full fertility service lineup. The $750,000 deal combines cash and preferred stock, with founder Dr. James Donahue remaining as leader. (Link)
  • Enjoin acquires Paediatric Resource Group to expand paediatric and adult CDI, APR‑DRG and physician advisor solutions for U.S. hospitals The acquisition combines Enjoin’s adult DRG assurance capabilities with PRG’s paediatric and neonatal CDI expertise to create a unified, tech-enabled revenue integrity platform. It enhances support for children’s and acute-care hospitals through utilization review and denials management, expanding nationwide CDI services under 3 Boomerang’s strategic healthcare platform. (Link)
  • Sentact acquires Performance Health Partners and Vizient Patient Safety Organization to build an integrated, analytics‑driven patient safety and incident reporting platform across U.S. care settings The acquisitions expand Sentact’s patient safety capabilities by integrating Performance Health Partners’ advanced incident management system and the Vizient Patient Safety Organization’s nationwide collaborative. Combined, they enhance data-driven risk analysis, workflow automation, and advisory support to help healthcare providers identify risks, improve safety practices, and elevate clinical outcomes systemwide. (Link)
  • Prosperous Health acquires Peninsula Health Center to expand integrated outpatient mental health and addiction services across Palos Verdes and the South Bay The merger creates a comprehensive behavioral health network offering detox, outpatient, and long-term therapy within integrated care plans for addiction and mental illness. Combining Prosperous Health’s physician-led model with Peninsula’s accredited programs enhances local access, continuity of care, telehealth services, and collaboration with hospitals and public health partners. (Link)
Neil Johnson No Comments

Recently Released Industry Report: Longevity Emerging Infrastructure in Preventative Health Dec 2025

Longevity-Emerging-Infrastructure-for-Preventative-Health_Report_Dec2025-1Download

Longevity is increasingly capturing attention of investors due to the explosive growth—but what does it truly entail?
In our recently released industry paper “Longevity: The Emerging Infrastructure of Preventative Health,” we examine current market dynamics, distill the complexities into a practical framework, highlighting recent trends, investments and include an optional in-depth exploration of the underlying science.

This industry paper aims to provide investors, analysts, and stakeholders with the essential knowledge to effectively engage with and benefit from this emerging Longevity industry.

Highlights Include:
– What is Healthcare Longevity?
– Market Drivers and Recent Investment Activity
– Key Longevity Sector Discussions:
– Clinical Delivery Models
*Geroscience and Therapeutics
*Precision Diagnostics and Predictive Analytics
*Data & AI Systems
*Psychological and Behavioral Health
*Hormonal and Reproductive Longevity
– Longevity Clinics – A Maturing Market / Emerging Pattern and Investment Opportunity
– Private Equity and Venture Investments
Shore Capital Partners, Boyne Capital, Capitala Group, Platt Park Capital, Panacea Venture, RA Capital Management, BOLD Capital Partners, Khosla Ventures, Gaingels, Longevity Science Foundation, ARCH Venture Partners

Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Dec 15th 2025

LECO_Weekly-Healthcare-News_12-15-2025Download
  • Novo Nordisk completes $4.7B acquisition of Akero Therapeutics (Nasdaq: AKRO) with additional $0.5B CVR tied to EFX approval Akero Therapeutics becomes a wholly owned subsidiary following the acquisition, delisting its shares from Nasdaq. The agreement includes additional payment contingent on FDA approval of EFX for MASH-related cirrhosis. The move strengthens Novo Nordisk’s liver and metabolic disease portfolio and expands its U.S. research and development operations. (Link)
  • Teleflex (NYSE: TFX) divests OEM, urology, and acute care units in $2B deals with Montagu, Kohlberg, and Intersurgical Teleflex is restructuring to prioritize its cardiovascular portfolio through divestments totalling $2 billion. Montagu and Kohlberg will acquire its OEM division, while Intersurgical will buy acute care and urology lines. Proceeds will partly fund a $1 billion share repurchase, with both deals expected to close in late 2026. (Link)
  • Lumexa Imaging (NASD: LMRI) raises nearly $463M in IPO, earns Moody’s credit upgrade after debt reduction plan The IPO valued Lumexa Imaging at $1.76 billion, with proceeds mainly used to refinance debt and extend maturities, reducing obligations by over $370 million. Moody’s upgraded its rating due to improved credit strength. Founded in 2018, the company operates 184 imaging centers and continues expanding through acquisitions and AI initiatives. (Link)
  • Cycle Pharmaceuticals to acquire Applied Therapeutics (Nasdaq: APLT) to advance CNS rare disease treatments through lead drug candidate Govorestat Applied Therapeutics shareholders will receive cash and contingent value rights tied to regulatory and sales milestones under the merger agreement. Cycle will provide up to $8.5 million in bridge funding to support operations until closing. The board unanimously approved the deal, expected to complete in early 2026. (Link)
  • HarmonEyes completes acquisition of iFocus Health to expand AI-driven solutions for ADHD treatment The merger integrates iFocus Health’s AI technology into HarmonEyes’ behavioral health platform to advance personalized ADHD care. Combining data analytics and machine learning, the partnership aims to improve diagnosis, treatment, and patient outcomes while expanding evidence-based, AI-driven mental health solutions for broader accessibility and clinical scalability. (Link)
  • Handspring Health acquires Joon Care to expand paediatric and adolescent behavioral health services The merger combines Handspring Health’s paediatric care focus with Joon Care’s virtual therapy model to enhance youth mental health services. It expands market reach through Joon’s Washington base and payer ties while integrating technology for improved engagement and outcomes, supporting Handspring’s growth and evidence-based, scalable care model. (Link)
  • Perimeter Solutions to acquire Medical Manufacturing Technologies in $685 million cash deal The transaction adds Medical Manufacturing Technologies’ expertise in minimally invasive device production to Perimeter Solutions’ portfolio, aligning with its strategy to invest in high-margin growth sectors. Funded by debt and cash, the deal expands Perimeter’s presence into medical manufacturing and is expected to close in early 2026 pending approval. (Link)
  • AMSURG acquires Advanced Center for Surgery to expand into Central Pennsylvania outpatient market The deal adds a 12,500-square-foot surgical center in Altoona with four operating rooms and 17 specialists to AMSURG’s network. Known for outpatient joint replacements, the facility strengthens AMSURG’s Pennsylvania presence and supports its mission to empower independent physicians and expand access to quality, value-based outpatient surgical care. (Link)
  • Select Medical acquires Landmark Hospital of Savannah from Landmark Holdings of Florida to expand long-term acute care services The acquisition adds a 50-bed long-term acute care hospital in Savannah to Select Medical’s network, replacing its former local facility. The site now treats medically complex patients needing extended recovery. This expansion strengthens Select Medical’s Southeast presence and supports its nationwide growth in post-acute and rehabilitation services. (Link)
  • Mercy Health and Lifepoint Health open new 72-bed Behavioral Hospital in Youngstown to expand mental health and substance abuse care The new 72-bed behavioral hospital provides inpatient care for mental health and substance use disorders, including programs for veterans and first responders. Using evidence-based, trauma-informed methods, it aims to ease ER burdens and improve community support, with inpatient admissions starting in January and outpatient services launching in May. (Link)
Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Dec 8th 2025

LECO_Weekly-Healthcare-News_12-8-2025Download
  • Hims & Hers Health (NYSE: HIMS) to acquire YourBio Health to add patented, pain-free TAP and HALO blood sampling technology to its wellness platform The acquisition will integrate virtually painless microneedle blood collection into a broader direct‑to‑consumer health platform, enabling fast, high‑quality capillary sampling outside traditional clinics. Protected microtechnology around device design, sample handling, and integration supports future test expansion, while incoming scientific and executive leaders will steer development of more user‑friendly diagnostics after the all‑cash deal closes. (Link)
  • Overjet acquires Toledo AI startup DentalBee to combine voice-driven documentation with dental imaging in a unified clinical intelligence platform The transaction pairs real-time voice capture of periodontal measurements, notes, and referral details with AI analysis of X‑rays to create fully structured dental records while easing documentation burden for clinicians. It also underscores Northwest Ohio’s emergence as an AI hub, with regional economic development groups credited for helping the startup reach acquisition. (Link)
  • Joi + Blokes acquires HerMD to build a nationwide virtual women’s health platform for menopause, sexual health, and hormonal care The merger will expand access to longer virtual consults with hormone and menopause specialists, broader treatment options, and preventive lab support in every state, while adding research participation opportunities. HerMD’s education-first approach will drive new national learning initiatives as the combined platform works to deliver more consistent, empathetic, evidence-based care to underserved midlife women. (Link)
  • Lightbeam Health Solutions acquires Syntax Health to integrate value-based contracting and actuarial modelling into its AI-enabled population health platform The acquisition adds a contract‑modelling engine and actuarial talent into a broader value‑based care operating system, allowing payers and providers to rapidly simulate deals, align on assumptions, and project financial results with more confidence. By tying benchmarking and forecasting directly to contract design, the combined platform aims to reduce administrative complexity and refocus attention on population outcomes. (Link)
  • Avandra Health acquires DatCard Systems and Sorna Corporation to build a unified global medical imaging and clinical data platform for patient care and research The enlarged platform will connect distribution tools already embedded at thousands of sites with a federated, de‑identified imaging network, making it easier for hospitals to share studies and for life sciences partners to tap high‑value data. By investing in upgrades and support while preserving existing brands, the organization aims to unlock siloed imaging for both care and research. (Link)
  • Ciba Health partners with Quikcard to launch personalized, prevention‑first metabolic and chronic care programs for Canadians The partnership brings structured 12‑month programs with dietitian and health‑coach support, personalized plans, and continuous tracking to help members address metabolic risk and chronic conditions through lifestyle change rather than medication alone. Validated outcomes include meaningful HbA1c drops, sharply reduced overall drug use and costs, and GLP‑1 Step Down participants lowering GLP‑1 dependence while losing weight over six months. (Link)
  • XRHealth acquires Innerworld to build an immersive, stepped-care XR platform for mental health and rehabilitation The combined platform will pair always‑on, community‑based mental health support—via live events, facilitator‑led groups, and global peer interaction—with existing VR/AR treatments for pain, rehab, PTSD, stress, addiction, and OCD. By adding Innerworld’s founder as chief clinical officer and building on prior XR acquisitions, the company is constructing a stepped‑care, AI‑enhanced XR ecosystem spanning self‑help to clinician‑guided therapy. (Link)
  • Cerbo acquires OptiMantra, via its financial sponsors Search Fund Partners, Applied Equity Partners, Manifestations Capital, Hunter Search Capital, Endurance Search Partners, and Red Forest Capital to build AI-powered practice platform for specialty and integrative care The merger creates a single EMR and practice‑management platform for integrative, functional, direct primary care, concierge, behavioral health, and IV/injectable practices, targeting the operational needs of membership‑ and cash‑pay models. Backed by multiple financial sponsors, the combined team will co‑develop AI‑enabled workflows, CRM-driven growth tools, and upgraded payment capabilities while keeping founders engaged and a customer‑first culture intact. (Link)
  • BriteLife Recovery acquires Summit Behavioral Health to add intensive outpatient services to its East Coast addiction treatment network The deal extends care into flexible day and evening intensive outpatient programming at the Princeton Junction site, supported by transportation, alumni services, family recovery programming, and enhanced staff training. BriteLife’s broader network across several East Coast states, plus insurance acceptance and scholarships, is intended to make trauma‑informed, relationship‑centered treatment more accessible. (Link)
  • CQ Medical acquires Bionix Radiation Therapy business unit to expand global radiotherapy positioning and marking portfolio The acquisition brings additional radiotherapy accessories and a seasoned sales team under the same umbrella, broadening an existing suite of positioning, immobilization, and image‑guided treatment devices used in oncology. CQ Medical plans to absorb the new product lines into its current manufacturing footprint while Bionix redirects attention and investment to its remaining ambulatory care portfolio. (Link)
  • Natera (NASD: NTRA) acquires Foresight Diagnostics in up to $450 million deal to expand minimal residual disease cancer testing portfolio The transaction adds ultra‑sensitive PhasED‑Seq assays that can detect lymphoma relapse at very low circulating tumour DNA levels long before standard imaging, alongside a CLIA‑registered lab and lymphoma expertise that deepen the existing MRD offering. It follows settlement of past IP disputes and comes amid strong cancer testing growth but continued net losses. (Link)
  • Paradigm Health raises $78 million Series B from ARCH Venture Partners, DFJ Growth, F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and American Cancer Society’s BrightEdge Fund to expand AI-enabled clinical trial infrastructure The platform links biopharma sponsors with 166 provider organizations and 2,100 care sites across 45 states. Automated matching and site-feasibility tools let health systems enrol up to four times faster and reduce clinician burden, while a new design service embeds interventional and pragmatic trials directly into routine workflows and expands into neuroscience, cardiovascular, and metabolic research. (Link)
  • Artera raises $65 million from Lead Edge Capital, Jackson Square Ventures, Health Velocity Capital, Heritage Medical Systems, and Summation Health Ventures to scale agentic AI for patient communication The company is using a decade of real‑world communication data to train AI that automates routine scheduling, intake, billing, and messaging across more than 1,000 provider organizations and 2 billion yearly interactions. Its “flow agents” already handle most exchanges without staff, while co‑pilot tools summarize, translate, and surface priority outreach, saving substantial administrative time. (Link)
  • Curi Bio raises $10 million Series B led by DreamCIS to scale human iPSC-based preclinical platforms and advanced functional data analysis for drug discovery Curi Bio is expanding a platform that uses high‑purity human iPSC‑derived cells, tissue‑specific 3D biosystems, and rich functional data to predict human drug responses more accurately than animal or 2D models. These assays guide candidate selection and IND decisions across multiple diseases, while partner DreamCIS contributes clinical research and regulatory expertise to boost trial success. (Link)
  • Lyric Bio, Inc. raises $6.6 million seed round led by The Venture Collective, with Black Diamond Ventures, Draper Associates, Lucas Venture Group, Meiji Seika Pharma, SOSV, and others to advance donor‑derived therapeutics biomanufacturing Lyric Bio is building ultra‑high‑density 3D bioreactors that mimic human tissue to manufacture donor‑derived therapies at scale, starting with IVIg and SCIg in a $20 billion market. By targeting up to 100x efficiency gains, the team aims to slash costs, cut reliance on human donors, and deliver more consistent, accessible immunoglobulin products. (Link)
Neil Johnson No Comments

News Healthcare Deals, Investments & Update Week ending Dec 1st 2025

LECO_Weekly-Healthcare-News_12-1-2025Download
  • Patient Square Capital completes $2.6 billion take-private acquisition of Premier, Inc (NASD: PINC), paying $28.25 per share in all-cash deal. The deal takes Premier private and keeps its operations focused on powering healthcare improvement through analytics, supply chain offerings, collaboratives, and advisory services. As part of a larger healthcare-focused portfolio, the company is expected to use additional capital and expertise to enhance technology-driven tools that help providers improve outcomes and reduce costs. (Link)
  • Bruker Corporation (NASD: BRKR) acquires AST Revolution to advance WAVE and Arc rapid antimicrobial susceptibility testing technologies and expand clinical diagnostics portfolio The deal shifts a revitalized rapid testing platform into a larger diagnostics ecosystem, keeping focus on delivering quicker, clinically actionable antimicrobial susceptibility results. With prior investment having stabilized and advanced the WAVE and Arc systems, the new owner is expected to use its scale, market access, and technical depth to speed adoption in laboratories and hospitals. (Link)
  • MDI NetworX acquires Cobalt MedPlans (Clarity Performance Solutions) from Cobalt Health Solutions, a Blue Cross and Blue Shield of Kansas City Subsidiary, to Expand U.S. Payer Services and Deploy InsightPro AI Platform The deal adds 250 U.S. staff and two Kansas delivery centers, lifting the company’s global workforce above 7,500 and growing its domestic operations to four sites. It plans to intensify investment in automation, analytics, and workforce capabilities to deliver scalable, end-to-end payer operations while tightening control of administrative costs. (Link)
  • US Fertility partners with L Catterton and Amulet Capital Partners in new co-lead investor structure to expand access to advanced reproductive care across the U.S. The updated ownership structure preserves significant physician ownership while adding growth capital and consumer-health expertise to scale US Fertility’s clinics, labs, and research programs. It supports broader access to IVF, IUI, genetic testing, and related services, while reinforcing a physician-led, patient-centered care model for tens of thousands of new patients annually. (Link)
  • MedEdge Holdings launches with $450 million management-led buyout to integrate Abyrx’s biomaterials portfolio and Kairuku’s surgical SaaS platform The holding company will merge biomaterials and surgical software capabilities to streamline product sourcing, inventory control, and case coordination for hospitals and OR teams. Profitable operations plus new capital will fund acquisitions of 10–15 commercial-stage products, aiming to cut administrative complexity while broadening access to next‑generation surgical technologies. (Link)
  • FluidAI Medical acquires Emmetros Limited, developer of SparxConnect, to strengthen AI-driven Stream Inara patient engagement The integration focuses on stronger postoperative monitoring and communication, using collaboration tools to guide patients before procedures and through home recovery. It supports earlier discharge while preserving visibility into outcomes and patient‑reported data, and complements existing monitoring, surgical decision support, and recovery programs to boost throughput, bed utilization, and personalized recovery planning. (Link)
  • Innova Therapeutics acquires Enci Therapeutics to advance IVT-8086, a first-in-class monoclonal antibody targeting SFRP2 in solid and hematologic cancers The deal centralizes control of IVT-8086 to accelerate its development as a targeted therapy against a key signalling pathway driving angiogenesis, tumour growth, immune evasion, and metastasis. Strong preclinical data support its potential both as monotherapy and in combination with checkpoint inhibitors, alongside a companion diagnostic to guide detection, prognosis, and relapse monitoring. (Link)
  • MiCare Path acquires Compwell, LLC to accelerate national expansion of AI-powered virtual care platform The platform now supports large, multispecialty patient panels with reimbursable programs for remote monitoring and ongoing care management. New capital and the Compwell integration will grow clinical services, deepen health system collaborations, and accelerate AI-driven workflow automation, enabling more proactive, personalized virtual care that extends clinician support into patients’ daily lives. (Link)
  • Brown’s Medical Imaging and Prestige Medical Imaging merge to expand nationwide, multi-vendor medical imaging service capabilities The merged business broadens nationwide coverage while maintaining a vendor-agnostic service model with strong uptime and response commitments. A 150‑plus engineer field force provides fast remote and onsite support, underpinned by a customer‑first, end‑to‑end service philosophy. Leadership promotions reinforce continuity and position the company for its next phase of growth. (Link)
  • AleraCare, backed by Hildred Capital Management, to merge with Pure Healthcare to Form National Platform for Ambulatory Infusion and Specialty Care The merged platform operates 77 infusion centers in 14 states, pairing complex-chronic-care expertise with expanding home and alternate-site services. A unified contracting and technology backbone supports payors, providers, and biopharma with faster therapy starts, better adherence, and AI-enabled scheduling, benefits checks, and real-time outcomes tracking, while maintaining a safety- and compassion-focused culture. (Link)